Gut organoid helped to define leaky gut and could aid in treatment development
Research has shown that leaky gut, the break down of gut lining junctions, could be targeted to reduce inflammation using metformin using an organoid model.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Research has shown that leaky gut, the break down of gut lining junctions, could be targeted to reduce inflammation using metformin using an organoid model.
Scientists using a new motor neuron disease (MND) model have shown astrocytes may protect neurons from toxic TDP-43 protein aggregates in the early stages of disease.
Scientists in Japan have identified an important protein that can impact the course of cancer and its fate in the human body.
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
A research team has shown that a key difference between neurogenic and non-neurogenic tissues is cross-linking proteins causing stiffness, a discovery that could be used to create new brain injury therapies.
Studies in mice have shown that the G-1 compound reduces obesity and the effects of diabetes by burning extra calories, report researchers.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
A molecular 'switch' that controls the immune machinery responsible for chronic inflammation has been identified which could help treat or even reverse the development of age-related conditions like Alzheimer's, Parkinson's, cancer and diabetes.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Research into age-related chronic inflammatory disorders has identified an ‘off switch’ on the NLRP3 inflammasome that could be targeted in new therapies.
Researchers have found that half of public and charity support for health research over the past 14 years has been for studying the cause and progression of disease.
Researchers have revealed that the disruption of oligodendrocytes, which produce myelin, may be a cause of autism spectrum disorder, so presents a therapeutic target.
Research into alternative stem cell sources has identified urine derived renal progenitor cells (UdRPCs) as a possible option for use in regenerative kidney therapies in the future.
Researchers have screened thousands of drugs to discover that C1 effectively blocks the production of amyloid fibrils, so could be an effective therapeutic.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.